J&J to acquire Aragon for $650M upfront + up to $350M milestones ($1B total); pre-close, Aragon spun out non-AR (estrogen receptor degrader) program as Seragon Pharmaceuticals.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedJun 17, 2013
ClosedAug 19, 2013
Deal value$1.0B
Deal typeAcquisition/Merger
Therapeutic areaCastration-resistant prostate cancer (CRPC)
IndicationsCastration-resistant prostate cancer (CRPC)